Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 109ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
0
4
0
3
1
2
0
1
0
Synonym Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Anwendungen A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
CAS Nummer: 75330-75-5
Reinheit: ≥97%
Molekulargewicht: 404.54
Summenformel: C24H36O5
* Schauen Sie auf das Analysezertifikat (CoA), um die genauen Daten (inkl. Wassergehalt) Ihrer Produktionscharge (Lot) zu sehen.
Bewerten Sie dieses Produkt und erhalten Sie 15 CruzCredits

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


Literaturhinweise

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

Aggregatzustand :
Solid
Erhaltene Form :
Non-native source; synthetic
Löslichkeit :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
LAGERUNG: :
Store at -20° C
Schmelztemperatur :
175.4° C
Sidepunkt :
~559.2° C at 760 mmHg (Predicted)
Dichte :
~1.1 g/cm3 (Predicted)
Brechungsindex :
n20D 1.53
Optische Aktivität :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Ki-Daten :
HMG-CoA reductase: Ki= 0.6 nM
Ausschließlich für Forschungszwecke. Nicht Geeignet für Verwendung in Diagnostik oder Therapie.
Deutsche WGK :
3
RTECS :
EK7907000
PubChem CID :
53232
Merck Index :
14: 5586
MDL-Nummer :
MFCD00072164

SDS (MSDS) herunterladen

Analysenzertifikat

Um PDF-Dokumente zu Drucken oder zu Bearbeiten
benötigen Sie Adobe Acrobat Reader

Lovastatin  Publikationen

Lesen Sie wie andere Anwender Lovastatin eingesetzt haben. Klicken Sie auf den jeweiligen Eintrag um den entsprechenden PubMed-Abstract abzurufen .

Produktreferenz 1 bis 7 von 7 insgesamt

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

Produktreferenz 1 bis 7 von 7 insgesamt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 128ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 22ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. ist weltweit führend in der Entwicklung von Produkten für den biomedizinischen Forschungsmarkt. Rufen Sie uns an, gebührenfrei unter 00800 4573 8000. .
Copyright © 2007-2020, Santa Cruz Biotechnology, Inc. Alle Rechte vorbehalten. "Santa Cruz Biotechnology", das Santa Cruz Biotechnology, Inc. Logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", das San Juan Ranch Logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz" und "EZ Touch" sind eingetragene Warenzeichen der Santa Cruz Biotechnology, Inc. Alle genannte Warenzeichen sind Eigentum der jeweiligen Inhaber. Alle Rechte vorbehalten.